The global Cardiometabolic Drugs Market size reached USD 50 Billion in 2021. The sales of cardiometabolic drugs are estimated to surpass a valuation of USD 70 Billion by 2032, rising at a CAGR of 4% to 5% during the forecast period 2022 to 2032.
Driven by the rising emphasis on the development of novel drugs that offers better results with minimal side effects, the demand for cardiometabolic drugs is projected to top USD 55 Billion by 2022.
| Report Attribute | Details |
|---|---|
| Cardiometabolic Drugs Market Base Year Value (2021) | USD 50 Billion |
| Cardiometabolic Drugs Market Expected Value (2022) | USD 55 Billion |
| Cardiometabolic Drugs Market Anticipated Value (2032) | USD 70 Billion |
| Cardiometabolic Drugs Market Projected Growth Rate (2022 to 2032) | 4% to 5% CAGR |
Cardiometabolic drugs are therapeutics medications purposefully used for a vast composition of metabolic disorders and dysfunction including cardiovascular diseases, obesity, diabetes, hypertension, dyslipidemia, central adiposity, and others.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Due to increasing fast-paced lifestyles, changing eating habits, and rising stress levels, a substantial rise in the burden of lifestyle diseases such as diabetes, obesity, hypertension, and others is being witnessed, creating demand for treatment drugs.
For instance, according to the International Diabetic Foundation, nearly 537 million adults between the age of 20 to 79 are living with diabetes across the world and the number is estimated to reach 643 million by 2030.
As cardiometabolic disorders are extensively used by diabetic patients for diverse applications, such as insulin resistance, growing diabetic population is projected to create high remunerative opportunities in the global market.
There are number of side effects associated with the consumption of cardiometabolic drugs such as antidiabetics, anticoagulants, hypertension, dyslipidemia drug, and others such as dyspepsia, vomiting, nausea, prolonged nosebleeds, passing of blood in urine, and others. Hence, rising awareness regarding such severe adverse effects on health is hindering the sales of cardiometabolic drugs in the market.
Principal Consultant
As per Future Market Insights, North America is forecast to account for the lion’s share in the global cardiometabolic drugs market between 2022 and 2032.
Cardiometabolic disorders and conditions involve a group of abnormalities that are interrelated, leading to a diverse constellation of cardiometabolic drugs used for each indication to limit the disease effect.
The prevalence of cardiovascular diseases is rising at a rapid pace across North America, due to the increasing pollution, smoking, opioid use, and others. According to the Centers for Disease Control and Prevention, nearly 18.2 million adults or around 6.7% of the population across the USA have coronary heart disease.
As cardiometabolic drugs play a crucial role in limiting the effect of these diseases along with their treatments, increasing burden of cardiovascular diseases is estimated to bolster the sales in the North America market.
FMI reveals that South Asia is anticipated to emerge as a highly lucrative market for cardiometabolic drugs during the forecast period 2022 to 2032.
With growing trend of personalized medication and rising demand for more effective drugs with minimal to no side effects, key manufacturers are focusing on research and development activities for the development of novel drugs.
For instance, in 2020, Natco Pharma, an Indian multinational pharmaceutical company announced launching a novel anti-blood clot medication, Rivaroxaban, under the brand name Xarelto. A multiplicity of such new product launches are expected to favor the demand for cardiometabolic drugs in the South Asia market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the leading players in the cardiometabolic drugs market are AbbVie Inc,, Besins Healthcare SA., Natco Pharma, Gilead Sciences Inc, Sanofi, InovoBiologic Inc, Carmel Biosciences Inc, Genfit SA, Kochi Prefecture, Cardax Pharmaceuticals, Inc., Abeille Pharmaceuticals, Inc., and others.
Attributed to the presence of such high number of participants and increasing emphasis on the development and launch of for novel drugs, the market is highly competitive.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 4% to 5% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2020 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Drug Class, Indication Type, Distribution Channel, Region |
| Countries Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East and Africa |
| Key Companies Profiled | Novartis; GlaxoSmithKline Plc.; Merck & Co., Inc.; Pfizer Inc; Bayer HealthCare Pharmaceuticals Inc.; Par Pharmaceutical; Romark Laboratories, L.C.; Lupin Pharma; Schering Corporation; Others |
| Customization | Available Upon Request |
FMI projects the sales of cardiometabolic drugs in the market is expected to rise at 4% to 5% value CAGR by 2032
The global cardiometabolic drugs market is expected to be dominated by North America over the forecast period 2022 to 2032.
AbbVie Inc,, Besins Healthcare SA., Natco Pharma, Gilead Sciences Inc, Sanofi, InovoBiologic Inc, Carmel Biosciences Inc, Genfit SA, Kochi Prefecture, Cardax Pharmaceuticals, Inc., Abeille Pharmaceuticals, Inc., and others are some of the leading players in the key cardiometabolic drugs market.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Cardiometabolic Drugs Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 5. Global Cardiometabolic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Drug Class 5.1. Instruments 5.2. Accessories 6. Global Cardiometabolic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Route of Administration 6.1. Portable 6.2. Non-Portable 7. Global Cardiometabolic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Indication 7.1. Plastic Surgery 7.2. Cardiothoracic Surgery 7.3. General Surgery 7.4. Orthopedic Surgery 7.5. Other Indications 8. Global Cardiometabolic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distribution Channel 8.1. Hospitals 8.2. Ambulatory Surgical Centers 8.3. Clinics 8.4. Medical Institutions/Laboratories 8.5. Others Distribution Channel 9. Global Cardiometabolic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 9.1. North America 9.2. Latin America 9.3. Europe 9.4. East Asia 9.5. South Asia & Pacific 9.6. MEA 10. North America Cardiometabolic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11. Latin America Cardiometabolic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12. Europe Cardiometabolic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13. East Asia Cardiometabolic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 14. South Asia & Pacific Cardiometabolic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 15. MEA Cardiometabolic Drugs Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 16. Key Countries Cardiometabolic Drugs Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. F. Hoffmann-La Roche Ltd 18.2. Boehringer Ingelheim International GmbH 18.3. Merck & Co., Inc 18.4. Lupin 18.5. Teva Pharmaceutical Industries Ltd. 18.6. Biocon 18.7. Novo Nordisk A/S 18.8. Abbott 18.9. Bayer AG 18.10. Merck KGAA 18.11. AstraZeneca 18.12. Takeda Pharmaceutical Company Limited 18.13. Sanofi Angiplast Pvt. Ltd. 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Cardiometabolic Drugs Market
